TY - JOUR T1 - First Line Gemcitabine/Pazopanib in Locally Advanced and/or Metastatic Biliary Tract Carcinoma. A Hellenic Cooperative Oncology Group Phase II Study JF - Anticancer Research JO - Anticancer Res SP - 929 LP - 938 DO - 10.21873/anticanres.14026 VL - 40 IS - 2 AU - JOSEPH SGOUROS AU - GERASIMOS ARAVANTINOS AU - GEORGIA-ANGELIKI KOLIOU AU - GEORGE PENTHEROUDAKIS AU - FLORA ZAGOURI AU - AMANDA PSYRRI AU - DIMITRA IOANNA LAMPROPOULOU AU - STAMATINA DEMIRI AU - DIMITRIOS PECTASIDES AU - EVANGELIA RAZIS AU - GEORGE FOUNTZILAS AU - EPAMINONTAS SAMANTAS Y1 - 2020/02/01 UR - http://ar.iiarjournals.org/content/40/2/929.abstract N2 - Background/Aim: The efficacy of gemcitabine-based chemotherapy in locally advanced/metastatic biliary tract carcinoma is limited. The aim of this trial was to assess the activity of a novel gemcitabine-pazopanib combination in such patients. Patients and Methods: In this phase II, multicenter trial, patients with histologically/cytologically confirmed biliary tract carcinoma, previously untreated for advanced disease, received 1000 mg/m2 of gemcitabine on days 1 and 8 every 21 days and 800 mg of pazopanib once daily continuously for 8 cycles, followed by pazopanib maintenance. The primary endpoint was objective response rate (ORR). Results: A total of 29 patients (median age; 69 years) were enrolled between June 2013 and March 2018. The ORR was 13.8% in the intent-to-treat and 19.1% in the per protocol population. The median progression-free and overall survival were 6.3 and 10.4 months, respectively. Conclusion: The low response rate precludes further testing of the combination in patients with biliary tract carcinoma. ER -